Literature DB >> 21626816

[The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke].

N A Shamalov, L V Stakhovskaia, D V Burenchev, I V Kichuk, T V Tvorogova, A Iu Botsina, A S Smychkov, O B Kerbikov, H Moessler, P Novak, V I Skvortsova.   

Abstract

The purpose of this randomized, double-blind, placebo-controlled study was to assess safety and efficacy of cerebrolysin used in dosage 50 ml in acute ischemic stroke. Forty-seven patients with ischemic stroke, aged 45-85 years, who were admitted to a clinical unit within the first 12 h after stroke onset were included in the study. A quantitative time-related MRI analysis of the dynamics of neurological deficit revealed the more rapid decrease of stroke volume to the 28th day in the group treated with cerebrolysin (45.4% versus 43.6% in the placebo-group (p < 0.05)). No side-effects of treatment with cerebrolysin was found. The results of this prospective, randomized, placebo-controlled study suggest the positive effect of cerebrolysin on the dynamics of volume lesion in patients with ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21626816

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  6 in total

Review 1.  Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.

Authors:  Brian Fiani; Claudia Covarrubias; Amelia Wong; Thao Doan; Taylor Reardon; Daniel Nikolaidis; Erika Sarno
Journal:  Neurol Sci       Date:  2021-01-30       Impact factor: 3.307

2.  Cerebrolysin for acute ischaemic stroke.

Authors:  Liliya Eugenevna Ziganshina; Tatyana Abakumova; Charles Hv Hoyle
Journal:  Cochrane Database Syst Rev       Date:  2020-07-14

Review 3.  Cerebrolysin for acute ischaemic stroke.

Authors:  Liliya Eugenevna Ziganshina; Tatyana Abakumova; Ludivine Vernay
Journal:  Cochrane Database Syst Rev       Date:  2016-12-05

4.  Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.

Authors:  Natan M Bornstein; Alla Guekht; Johannes Vester; Wolf-Dieter Heiss; Eugene Gusev; Volker Hömberg; Volker W Rahlfs; Ovidiu Bajenaru; Bogdan O Popescu; Dafin Muresanu
Journal:  Neurol Sci       Date:  2017-12-16       Impact factor: 3.307

5.  Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Peter Y M Woo; Joanna W K Ho; Natalie M W Ko; Ronald P T Li; Leo Jian; Alberto C H Chu; Marco C L Kwan; Yung Chan; Alain K S Wong; Hoi-Tung Wong; Kwong-Yau Chan; John C K Kwok
Journal:  BMC Neurol       Date:  2020-11-03       Impact factor: 2.474

Review 6.  Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials.

Authors:  Stefan Strilciuc; László Vécsei; Dana Boering; Aleš Pražnikar; Oliver Kaut; Peter Riederer; Leontino Battistin
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.